I haven’t written much about Rob Fannon and his Phase 1 Investor newsletter lately — this is the high end newsletter published by the folks at Stansberry and Associates, it’ll run you about $4,500 a year, and it’s largely focused on biotech companies. So is their advice worth more than the advice from less expensive [...]
This teaser comes in from the folks at Stansberry’s Phase 1 Investor service, which is their uber-expensive $5,000 subscription newsletter that purports to find the best opportunities in the smallest stocks. They have developed what they call the L-2 Indicator that tells them when to buy stocks, in this case gold stocks: “the ‘L-2 Indicator’ [...]
This teaser and the solution come in from our old friend Streetsifter, who has written up a few solutions in this space in the past — t0 the great appreciation of your Gumshoe. His solution has been confirmed by a few other readers who I know do a good job sniffing out solutions, so he’s [...]
So that’s an attention-getting claim, eh? Wait, it gets better. This one comes to us from Porter Stansberry at Phase 1 Investor, who would like us to pony up … get ready for it … $5,000 for entry into the exclusive group of investors who are going to find out — in a report released [...]
This one comes to us from Peter Stansberry as part of an ad for his Phase 1 Investor service … which he’d like you to subscribe to in exchange for learning about this fabulous company in a special report. In fact, he’s promising that his biotech analyst will reveal the name of this company on [...]